Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNYZ) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for Ligand Pharmaceuticals (LGNYZ) over the last 15 years, with Q3 2025 value amounting to $53.3 million.

  • Ligand Pharmaceuticals' Change in Acquisitions & Divestments fell 4122.22% to $53.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $176.3 million, marking a year-over-year decrease of 2714.81%. This contributed to the annual value of $229.4 million for FY2024, which is 5418.08% up from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported Change in Acquisitions & Divestments of $53.3 million as of Q3 2025, which was down 4122.22% from $44.8 million recorded in Q2 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' Change in Acquisitions & Divestments peaked at $132.9 million during Q1 2022, and registered a low of $1.8 million during Q4 2021.
  • Its 5-year average for Change in Acquisitions & Divestments is $46.2 million, with a median of $44.2 million in 2023.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first crashed by 9867.13% in 2021, then soared by 127578.43% in 2022.
  • Quarter analysis of 5 years shows Ligand Pharmaceuticals' Change in Acquisitions & Divestments stood at $1.8 million in 2021, then soared by 297.11% to $7.0 million in 2022, then surged by 648.28% to $52.4 million in 2023, then fell by 24.11% to $39.8 million in 2024, then soared by 33.87% to $53.3 million in 2025.
  • Its Change in Acquisitions & Divestments was $53.3 million in Q3 2025, compared to $44.8 million in Q2 2025 and $38.4 million in Q1 2025.